Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6956109 | 0.97 | PTPN1 (0.43) | PTPN1MAPTPOLBHPGDLMNA | |
| SCHEMBL9971603 | 0.94 | MAPT (0.41) | PTPN1MAPTPOLBHPGDLMNA | |
| SCHEMBL5448434 | 0.85 | MAPT (0.43) | PTPN1MAPTPOLBHPGDLMNA | |
| SCHEMBL6214305 | 0.85 | PPARA (0.46) | PTPN1MAPTPOLBHPGDLMNA | |
| SCHEMBL5457924 | 0.84 | MAPT (0.42) | PTPN1MAPTPOLBHPGDLMNA | |
| SCHEMBL4265630 | 0.84 | PTPN1 (0.51) | PTPN1MAPTPOLBHPGDLMNA | |
| SCHEMBL14720986 | 0.83 | MAPT (0.43) | PTPN1MAPTPOLBHPGDLMNA | |
| SCHEMBL9971599 | 0.80 | MAPT (0.42) | PTPN1MAPTPOLBHPGDLMNA | |
| SCHEMBL11983291 | 0.79 | MAPT (0.41) | PTPN1MAPTPOLBHPGDLMNA | |
| SCHEMBL14428540 | 0.78 | MAPT (0.46) | PTPN1MAPTPOLBHPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8557989-B2 | Electrochemical affinity biosensor system and methods | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20130213822-A1 | ELECTROCHEMICAL AFFINITY BIOSENSOR SYSTEM AND METHODS | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-8293904-B2 | Electrochemical affinity biosensor system and methods | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-8288544-B2 | Electrochemical affinity biosensor system and methods | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288544-B2 | Electrochemical affinity biosensor system and methods | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| EP-1646637-B1 | ELECTROCHEMICAL AFFINITY BIOSENSOR SYSTEM AND METHODS | ROCHE DIAGNOSTICS GMBH (DE) | 2012-08-15 | — | — | EP | disclosed |
| EP-1646637-B1 | ELECTROCHEMICAL AFFINITY BIOSENSOR SYSTEM AND METHODS | ROCHE DIAGNOSTICS GMBH (DE) | 2012-08-15 | — | — | EP | disclosed |
| EP-2465862-A1 | Mononuclear osmium complexes for use in biosensors | Roche Diagniostics GmbH (DE) | 2012-06-20 | — | — | EP | disclosed |
| EP-2465862-A1 | Mononuclear osmium complexes for use in biosensors | Roche Diagniostics GmbH (DE) | 2012-06-20 | — | — | EP | disclosed |
| US-20120125788-A1 | ELECTROCHEMICAL AFFINITY BIOSENSOR SYSTEM AND METHODS | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2012-05-24 | — | — | US | disclosed |
| US-20070054317-A1 | Electrochemical affinity biosensor system and methods | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070054317-A1 | Electrochemical affinity biosensor system and methods | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2007-03-08 | — | — | US | disclosed |
| EP-1646637-A2 | ELECTROCHEMICAL AFFINITY BIOSENSOR SYSTEM AND METHODS | Roche Diagnostics GmbH (DE) | 2006-04-19 | — | — | EP | disclosed |
| WO-2005026178-A2 | ELECTROCHEMICAL AFFINITY BIOSENSOR SYSTEM AND METHODS | ROCHE DIAGNOSTICS GMBH (DE) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054317-A1 | Electrochemical affinity biosensor system and methods | SIGLEC7, FCGR3B, FCER2 | PTPN1 1523/4885MAPT 4051/4885POLB 2853/4885 |
| US-20130213822-A1 | ELECTROCHEMICAL AFFINITY BIOSENSOR SYSTEM AND METHODS | SIGLEC7, FCGR3B, FCER2 | PTPN1 1523/4885MAPT 4051/4885POLB 2853/4885 |
| US-20120125788-A1 | ELECTROCHEMICAL AFFINITY BIOSENSOR SYSTEM AND METHODS | SIGLEC7, FCGR3B, FCER2 | PTPN1 1523/4885MAPT 4051/4885POLB 2853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.